A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine in the Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)

Trial Profile

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine in the Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2017

At a glance

  • Drugs Lofexidine (Primary)
  • Indications Opioid abuse
  • Focus Registrational; Therapeutic Use
  • Sponsors US WorldMeds
  • Most Recent Events

    • 03 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 01 Dec 2014 Planned End Date changed from 1 Sep 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov
    • 01 Dec 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top